News for Ascletis Pharma Inc. (1672.HK)

- First participants with obesity or overweight with at least one weight-related comorbidity have been dosed in a U.S. 13-week Phase IIa study of small molecule oral GLP-1 receptor agonist ASC30. - ASC30 oral once-daily tablet demonstrated up to 6.5% placebo-adjusted mean body weight reduction from baseline after four-week treatment in a U.S. Phase Ib study.

HONG KONG, June 9, 2025 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, 'Ascletis') announces that poster presentations on preliminary studies of its oral small molecule GLP-1 Receptor (GLP-1R) agonist ASC30 and adipose-targeted, muscle-preserving weight loss drug candidate ASC47 will be presented at the 85th Scientific Sessions of American Diabetes Association (ADA) in Chicago, U.S.

Denifanstat (ASC40) demonstrates impressive Phase III trial results, enhancing treatment success for acne. Notable improvements in efficacy compared to

ASC47, an adipose-targeted muscle-preserving weight loss drug candidate for the treatment of obesity, demonstrated a half-life of up to 26 days and 40 days, respectively, in Phase Ib single subcutaneous injection studies in healthy subjects with elevated low-density lipoprotein cholesterol (LDL-C) and patients with obesity, supporting once-monthly to once-bimonthly administration. ASC47 was safe and well tolerated in both healthy subjects with elevated LDL-C and patients with obesity. Previous preclinical data indicated that in a head-to-head diet-induced obese (DIO) mouse model, low dose ASC47 in combination with semaglutide demonstrated a 56.7% greater reduction in body weight compared to semaglutide monotherapy. U.S. Food and Drug Administration (FDA) clearance recognizes and supports a proof-of-concept clinical study of ASC47, an adipose-targeted thyroid hormone receptor beta (THRβ) selective agonist, in combination with an incretin drug. HONG KONG, March 12, 2025 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX:1672, 'Ascletis') announces encouraging pharmacokinetic and weight loss data from its ASC47 Phase Ib single subcutaneous injection studies in Australia in healthy subjects with elevated low-density lipoprotein cholesterol (LDL-C) (Part I) and in patients with obesity (Part II) (NCT06427590).

Sagimet Biosciences is progressing with Denifanstat research targeting MASH, acne, and cancer with promising Phase 2b trial results. Learn more on SGMT stock here.

- Up to 68.2% mean relative reduction in liver fat content from baseline among biopsy-confirmed metabolic dysfunction-associated steatohepatitis patients receiving 12-week treatment...

PI3K inhibitors are primarily used in the treatment of various cancers, including breast cancer, lymphoma, and leukemia. With the global burden of cancer...

The PD-1 and PD-L1 inhibitor market is anticipated to be driven in the coming years due to the rise in novel drugs and therapies and the increase in...

HANGZHOU and SHAOXING, China, Jan. 24, 2024 /PRNewswire/ -- Ascletis Pharma Inc. today announces dosing of the first patient in Phase III clinical trial of ASC40 for treatment of moderate to...

Denifanstat achieved statistically significant results on primary and multiple secondary endpoints in a 52-week clinical trial of 168 NASH patients with stage 2 or 3 fibrosis -  Primary efficacy...

The prevalence of Cancer has been rising over the past few years, which prompts the growing demand for treatment options. The increasing prevalence of...

The prevalence of Cancer has been rising over the past few years, which prompts the growing demand for treatment options. The increasing prevalence of...

/PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") today announces positive interim data from the Phase IIb expansion cohort (the "Expansion...

/PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") today announces the completion of enrollment of 120 patients in the Phase III registration...

The prevalence of Cancer has been rising over the past few years, which prompts the growing demand for treatment options. The increasing prevalence of...

The interest of Pharma and the research community in AXL inhibitors as anticancer agents has dramatically increased over the past years. The growing number...

The prevalence of cancer has been rising over the past few years, which prompts the growing demand for treatment options. The introduction of immune...

The introduction of ADCs into the market and the promising clinical results of more ADC prospects have increased industry interest in ADCs as a treatment...

SHANGHAI, Feb. 21, 2021 /PRNewswire/ -- Gannex, a wholly owned company of Ascletis Pharma Inc. (HKEX: 1672), fully dedicated to the R&D and commer...